Are Selective Serotonin Reuptake Inhibitors Safe for Drivers? What is the Evidence?

Clinical Therapeutics

Volumn 34, Issue 5, 2012, Pages 1070-1083

  Ravera, Silvia ^a   Ramaekers, Johannes G ^b   De Jong van den Berg, Lolkje T W ^a   De Gier, Johan J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Adverse effect; Automobile driving; Experimental research; Pharmacoepidemiologic studies; Selective serotonin reuptake inhibitors; Traffic accident

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LITHIUM; LORAZEPAM; MIRTAZAPINE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE; ZOPICLONE;

AGITATION; ANXIETY; BEHAVIOR DISORDER; CAR DRIVER; COGNITION; DEPRESSION; DIZZINESS; DRIVER LICENCE; DRIVING ABILITY; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; EATING DISORDER; FATIGUE; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; LAW; MAJOR DEPRESSION; MEDLINE; MONOTHERAPY; PERSONALITY DISORDER; PHARMACOEPIDEMIOLOGY; POSTTRAUMATIC STRESS DISORDER; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SLEEP QUALITY; SOMNOLENCE; TRAFFIC ACCIDENT; TRAFFIC SAFETY;

ACCIDENTS, TRAFFIC; ANTIDEPRESSIVE AGENTS; AUTOMOBILE DRIVING; DEPRESSION; HUMANS; PHARMACOEPIDEMIOLOGY; SEROTONIN UPTAKE INHIBITORS;

EID: 84860767336     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.04.002     Document Type: Review

References (67)

1. Verster J.C., Ramaekers J.G. Antidepressants and traffic safety. Drugs, Driving and Traffic Safety 2009, 307-313. Birkaeuser Verlag AG, Basel-Boston-Berlin, Switzerland. J.C. Verster, S.R. Pandi-Perumal, J.G. Ramaekers, J.J. de Gier (Eds.).
2. Katzung B.G. Basic and Clinical Pharmacology 2001, Lange Medical Books/McGraw-Hill, New York, NY. 8th ed.
3. Trindade E., Menon D., Topfer L.A., Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998, 159:1245-1252.
4. Wadsworth E.J., Moss S.C., Simpson S.A., Smith A.P. Psychotropic medication use and accidents, injuries and cognitive failures. Hum Psychopharmacol 2005, 20:391-400.
5. Walinder J. Comparative efficacy and safety of selective serotonin reuptake inhibitors in the short- and medium-term treatment of major depressive disorders. Nord J Psychiatry 1996, 50:55-59.
6. Westenberg H.G., Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract 2006, 60:482-491.
7. Sansone R.A., Sansone L.A. Driving on antidepressants: cruising for a crash?. Psychiatry 2009, 6:13-16.
8. An inventory of literature on the relation between drug use, impaired driving and traffic accidents (CT.97.EP.14) European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Accessed September 15, 2011. http://www.drugsandalcohol.ie/5308/1/1366-1591.pdf.
9. Ramaekers J.G. Pitfalls in estimating drug-related crash risk. Trends Pharmacol Sci 2003, 24:114-115.
10. Raes E., van den Neste T., Verstraete A.G. Drug use, impaired driving and traffic accidents Accessed September 15, 2011. http://www.emcdda.europa.eu/publications/insights/driving.
11. Strom B.L. Pharmacoepidemiology 1994, John Wiley & Sons Ltd, West Sussex, England. 2nd ed.
12. Hennekens C.H., Buring J.E. Epidemiology in Medicine 1987, Lippincott Williams & Wilkins, Philadelphia, Pa. 1st ed.
13. de Gier J.J., Ravera S., Monteiro S.P., Alvarez F.J. Establishment of criteria for a European categorisation system for medicines and driving: DRUID Deliverable 4.2.1 DRUID Work Package 4 Partners, Accessed October 10, 2011. http://www.druid-project.eu/cln_031/nn_107548/Druid/EN/deliverales-list/downloads/Deliverable__4__2__1,templateId=raw,property=publicationFile.pdf/Deliverable_4_2_1.pdf.
14. A guideline on Summary of Product Characteristics (SmPC) European Commission Enterprise and Industry Directorate-General, Accessed October 10, 2011. http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf.
15. Pil K., Raes E., van den Neste T., et al. Review of existing classification efforts: DRUID Deliverable 4.1.1 Accessed February 20, 2012. http://www.druid-project.eu/cln_031/nn_107548/Druid/EN/deliverales-list/downloads/Deliverable__4__1__1,templateId=raw,property=publicationFile.pdf/Deliverable_4_1_1.pdf.
16. Driving Under the Influence of Drugs, Alcohol and Medicines (DRUID), Accessed October 10, 2011. http://www.druid-project.eu/.
17. Gómez-Talegón T., Fierro I., Del Río M.C., Álvarez F.J. Establishment of framework for classification/categorisation and labelling of medicinal drugs and driving: DRUID Deliverable 4.3.1 Accessed October 10, 2011. http://www.druid-project.eu/cln_031/nn_107548/Druid/EN/deliverales-list/downloads/Deliverable__4__3,templateId=raw,property=publicationFile.pdf/Deliverable_4_3.pdf.
18. Ables A.Z., Baughman O.L. Antidepressants: update on new agents and indications. Am Fam Physician 2003, 67:547-554.
19. Goodnick P.J., Goldstein B.J. Selective serotonin reuptake inhibitors in affective disorders, I: basic pharmacology. J Psychopharmacol 1998, 12:S5-S20.
20. Masand P.S., Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 1999, 7:69-84.
21. Masand P.S., Gupta S. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 2002, 14:175-182.
22. Peretti S., Judge R., Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000, 403:17-25.
23. Downie G., Mackenzie J., Williams A. Pharmacology and Medicines Management for Nurses 2003, Churchill Livingstone, Edinburgh, Scotland. 3rd ed.
24. Williams D.A. Antidepressants. Foye's Principles of Medicinal Chemistry 2008, 547-600. Lippincott Williams & Wilkins, Philadelphia, PA. 6th ed. W.O. Foye, T.L. Lemke, D.A. Williams (Eds.).
25. Kasper S., Hoeflich G., Scholl H.P., Moeller H.J. Safety and antidepressants efficacy of selective serotonin re-uptake inhibitors. Hum Psychopharmacol 1994, 9:1-12.
26. Ferguson J.M. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001, 3:22-27.
27. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000, 58:19-36.
28. What are the real risks of antidepressants?. Harv Ment Health Lett 2005, 21:1-4. Anonymous.
29. Moret C., Isaac M., Briley M. Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharmacol 2009, 23:967-974.
30. Hampton T. Suicide caution stamped on antidepressants. JAMA 2004, 291:2060-2061.
31. Moller H.J., Baldwin D.S., Goodwin G., et al. Do SSRIs or antidepressants in general increase suicidality?. WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci 2008, 258(Suppl 3):3-23.
32. Neutel C.I., Patten S.B. Risk of suicide attempts after benzodiazepine and/or antidepressant use. Ann Epidemiol 1997, 7:568-574.
33. Wessely S., Kerwin R. Suicide risk and the SSRIs. JAMA 2004, 292:379-381.
34. Schatzberg A.F. New indications for antidepressants. J Clin Psychiatry 2000, 61(Suppl 11):9-17.
35. Iwamoto K., Takahashi M., Nakamura Y., et al. The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: a double-blind crossover trial. Hum Psychopharmacol 2008, 23:399-407.
36. Schmitt J.A., Ramaekers J.G., Kruizinga M.J., et al. Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J Psychopharmacol 2002, 16:207-214.
37. Wingen M., Bothmer J., Langer S., Ramaekers J.G. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005, 66:436-443.
38. Brunnauer A., Laux G., Geiger E., et al. Antidepressants and driving ability: results from a clinical study. J Clin Psychiatry 2006, 67:1776-1781.
39. Wingen M., Ramaekers J.G., Schmitt J.A. Driving impairment in depressed patients receiving long-term antidepressant treatment. Psychopharmacology (Berl) 2006, 188:84-91.
40. Grabe H.J., Wolf T., Gratz S., Laux G. The influence of polypharmacological antidepressive treatment on central nervous information processing of depressed patients: implications for fitness to drive. Neuropsychobiology 1998, 37:200-204.
41. Hindmarch I. The behavioural toxicity of the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1995, 9(Suppl 4):13-17.
42. Sherwood N. Comparative behavioural toxicity of the selective serotonin reuptake inhibitors. Hum Psychopharmacol 1995, 10:S159-S162.
43. Ramaekers J.G. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. J Clin Psychiatry 2003, 64:20-29.
44. Dumont G.J., de Visser S.J., Cohen A.F., van Gerven J.M.A. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br J Clin Pharmacol 2005, 59:495-510.
45. Barbone F., McMahon A.D., Davey P.G., et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998, 352:1331-1336.
46. Bramness J.G., Skurtveit S., Neutel C.I., et al. Minor increase in risk of road traffic accidents after prescriptions of antidepressants: a study of population registry data in Norway. J Clin Psychiatry 2008, 69:1099-1103.
47. Rapoport M.J., Herrmann N., Molnar F., et al. Psychotropic medications and motor vehicle collisions in patients with dementia. J Am Geriatr Soc 2008, 56:1968-1970.
48. Ravera S., van Rein N., de Gier J.J., de Jong-van den Berg L.T. Road traffic accidents and psychotropic medication use in the Netherlands: a case-control study. Br J Clin Pharmacol 2011, 72:505-513.
49. Rapoport M.J., Zagorski B., Seitz D., et al. At-fault motor vehicle crash risk in elderly patients treated with antidepressants. Am J Geriatr Psychiatry 2011, 19:998-1006.
50. Edwards J.G., Anderson I. Systemic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999, 58(Suppl 6):1207-1209.
51. Walsh J.M., Verstraete A.G., Huestis M.A., Morland J. Guidelines for research on drugged driving. Addiction 2008, 103:1258-1268.
52. Houwing S., Mathijssen R., Brookhuis K.A. Case-control studies. Drugs, Driving and Traffic Safety 2009, 107-120. Birkaeuser Verlag AG, Basel-Boston-Berlin, Switzerland. J.C. Verster, S.R. Pandi-Perumal, J.G. Ramaekers, J.J. de Gier (Eds.).
53. Communication from the Commission to the council for an action programme on road safety Commission of the European Communities, Accessed October 10, 2011. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:1993:0246:FIN:EN:PDF.
54. European Road Safety Action Programme: halving the number of road accident victims in the European Union by 2010: a shared responsibility Commission of the European Communities, Accessed October 10, 2011. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2003:0311:FIN:EN:PDF.
55. EU project ROSITA: Roadside Testing Assessment Accessed September 15, 2011. http://www.rosita.org/.
56. de Gier J.J., Alvarez F.J., Mercier-Guyon C., Verstraete A.G. Prescribing and dispensing guidelines for medicinal drugs affecting driving performance. Drugs, Driving and Traffic Safety 2009, 121-134. Birkaeuser Verlag AG, Basel-, Switzerland. J.C. Verster, S.R. Pandi-Perumal, J.G. Ramaekers, J.J. de Gier (Eds.).
57. Arrêté du 18 juillet 2005 pris pour l'application de l'article R. 5121-139 du code de la santé publique et relatif l'apposition d'un pictogramme sur le conditionnement extérieur de certains médicaments et produit Accessed October 10, 2011. http://admi.net/jo/20050802/SANP0522726A.html.
58. Medicinal products and driving Agence française de sécurité sanitaire des produits de santé (AFSSAPS), Accessed September 15, 2011. http://www.afssaps.fr/var/afssaps_site/storage/original/application/e5f2e48d5344bcfef6ca865ac63e7c3d.pdf.
59. The International Council on Alcohol, Drugs and Traffic Safety (ICADTS) categorization list ICADTS Working Group on Prescribing and Dispensing Guidelines for Medicinal Drugs affecting Driving Performance, Accessed September 15, 2011. http://www.icadts.nl/medicinal.html.
60. Council Directive 91/439/EEC of 29 July 1991 on driving licences, Accessed September 15, 2011. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:1991:237:0001:0024:EN:PDF.
61. Alvarez F.J., Fierro I., Vicondoa A., et al. Assessment of fitness to drive and cardiovascular diseases at the Spanish medical traffic centres. Circ J 2007, 71:1800-1804.
62. Legal approaches to drugs and driving European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), /html.cfm//index19034EN. html Accessed October 10, 2011. http://www.emcdda.europa.eu.
63. Walsh J.M., de Gier J.J., Christopherson A.S., Verstraete A.G. Drugs and driving. Traffic Inj Prev 2004, 5:241-253.
64. Álvarez F.J., del Rio M.C. Medicinal drugs and driving: from research to clinical practice. Trends Pharmacol Sci 2002, 23:441-443.
65. Rohrig T.P., Goodson L.J. A sertraline-intoxicated driver. J Anal Toxicol 2004, 28:689-691.
66. Akin A., Chaturvedi A.K. Selective serotonin reuptake inhibitors in pilot fatalities of civil aviation accidents, 1990-2001. Aviat Space Environ Med 2003, 74:1169-1176.
67. Orriols L., Salmi L.R., Philip P., et al. The impact of medicinal drugs on traffic safety: a systematic review of epidemiological studies. Pharmacoepidemiol Drug Saf 2009, 18:647-658.